Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators

BACKGROUND: Despite approval of immunotherapy for a wide range of cancers, the majority of patients fail to respond to immunotherapy or relapse following initial response. These failures may be attributed to immunosuppressive mechanisms co-opted by tumor cells. However, it is challenging to use conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jiakai, Wang, Yunfei, Shi, Leilei, Chen, Yuan, Xu, Chunyu, Saeedi, Arash, Pan, Ke, Bohat, Ritu, Egan, Nicholas A., McKenzie, Jodi A., Mbofung, Rina M., Williams, Leila J., Yang, Zhenhuang, Sun, Ming, Liang, Xiaofang, Rodon Ahnert, Jordi, Varadarajan, Navin, Yee, Cassian, Chen, Yiwen, Hwu, Patrick, Peng, Weiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887353/
https://www.ncbi.nlm.nih.gov/pubmed/33589527
http://dx.doi.org/10.1136/jitc-2020-001819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887353/
https://www.ncbi.nlm.nih.gov/pubmed/33589527
http://dx.doi.org/10.1136/jitc-2020-001819

Ejemplares similares